What is the role of nivolumab (Opdivo) in the treatment of renal cell carcinoma (RCC)?

Updated: May 21, 2019
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print
Answer

Nivolumab (Opdivo) is a monoclonal antibody to programmed cell death–1 protein (PD-1). In November 2015, nivolumab gained a new indication in the US for patients with advanced RCC whose disease progressed despite prior antiangiogenic therapy (ie, with VEGF inhibitors). Approval was based on the Checkmate-025 trial, which showed improved overall survival and fewer grade 3 or 4 adverse events than everolimus in a randomized, open-label, study of 821 patients with advanced clear-cell RCC who had received previous treatment with one or two regimens of antiangiogenic therapy. Median overall survival was 25.0 months with nivolumab and 19.6 months with everolimus (hazard ratio, 0.73; P = 0.002). Additionally, the objective response rate was 25% for nivolumab compared with 5% for everolimus (P <0.001).<ref>50</ref>


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!